Imiphumela esheshayo emizuzwini eyi-15-30 Ikhithi ye-antigen esheshayo AMRDT120

Ukuhlolwa okusheshayo kokutholwa kwekhwalithi kokungathathi hlangothi

amasosha omzimba ku-SARS-CoV-2 noma imigomo yayo egazini lonke, i-serum, noma i-plasma.

Ukucaciswa Kwephakheji: 40 T/kit, 20 T/kit, 10 T/kit, 1 T/kit.

Ukuzwela Okuhlobene: 96.97% (95%CI:83.35% ~99.99%)
Ukucaciswa okuhlobene: 100.00% (95%CI:97.29% ~100.00%)
Ukunemba: 99.50% (95%CI:96.94% ~99.99%)

Izikhwama ze-foil, ezinama-cassste okuhlola kanye nama-desiccants *20
I-assay buffer *20 izitsha;
Amaconsi alahlwayo*20;
I-Lancet *20
Lodine swab*20
Umyalelo wokusetshenziswa*1

Imiphumela esheshayo emizuzwini eyi-15-30 Ikhithi ye-antigen esheshayo i-AMRDT120 UKUSETSHENZISWA OKUHLOSIWE
I-SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) iyi-chromatographic immunoassay esheshayo yokutholwa kwekhwalithi yamasosha omzimba angathathi hlangothi ku-SARS-CoV-2 egazini lonke, i-serum, noma i-plasma.

Imiphumela esheshayo emizuzwini eyi-15-30 Ikhithi ye-antigen esheshayo AMRDT120 PRINCIPLE
I-SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) ingeyokuthola amasosha omzimba ku-SARS-CoV-2 noma emithini yayo yokugoma.I-cell surface receptor i-angiotensin converting enzyme-2 (ACE2) ihlanganiswe endaweni yomugqa wokuhlola kanye nesizinda esibophezelayo se-recombinant receptor-binding (RBD) esihlanganiswe nezinhlayiya ezikhombisayo.

Ngesikhathi sokuhlolwa, uma kukhona amasosha omzimba a-SARS-CoV-2 esampula, ingasabela nge-protein RBD-particle conjugate futhi ingasabeli ngeprotein evalwe ngaphambili i-ACE2.Ingxube ibe isithuthela phezulu kulwelwesi lwe-chromatographical ngesenzo se-capillary futhi ngeke ibanjwe i-antigen eboshwe ngaphambili.I-SARS-CoV-2 Neutralizing Antibody Rapid Test (COVID-19 Ab) iqukethe izinhlayiya ezimbozwe ngamaprotheni i-RBD.Amaprotheni ACE2 ambozwe endaweni yomugqa wokuhlola.